Two-Drug combo aims to wipe out breast cancer before surgery in BRCA carriers
NCT ID NCT05576389
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether giving fluzoparib (a PARP inhibitor) together with camrelizumab (an immunotherapy) before surgery can make HER2-negative breast cancer disappear completely in people with an inherited BRCA mutation. The trial enrolls 64 patients with early or locally advanced disease. Participants take fluzoparib pills twice daily and receive camrelizumab by IV once per cycle. The main goal is to see if the cancer is gone at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could become a new pre-surgery treatment that eliminates tumors in people with BRCA-mutated HER2-negative breast cancer, potentially avoiding the need for chemotherapy.
- What could go wrong
- This is an early-phase, single-arm study with only 64 participants, so results may not apply to everyone. The combination may cause side effects from both drugs, and it is not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERMLINE BRCA-MUTATED HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast Cancer, Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••